Association of XRCC2 rs2040639 with the survival of patients with oral squamous cell carcinoma undergoing concurrent chemoradiotherapy

Thomas Senghore; Wen-Chang Wang; Huei-Tzu Chien; You-Xin Chen; Chi-Kuang Young; Shiang-Fu Huang; Chih-Ching Yeh

doi:10.1016/j.gene.2020.145283

Association of XRCC2 rs2040639 with the survival of patients with oral squamous cell carcinoma undergoing concurrent chemoradiotherapy

Gene. 2021 Feb 5:768:145283. doi: 10.1016/j.gene.2020.145283. Epub 2020 Nov 1.

Authors

Thomas Senghore¹, Wen-Chang Wang², Huei-Tzu Chien³, You-Xin Chen⁴, Chi-Kuang Young⁵, Shiang-Fu Huang⁶, Chih-Ching Yeh⁷

Affiliations

¹ School of Public Health, College of Public Health, Taipei Medical University, Taipei, Taiwan; Department of Nursing and Reproductive Health, School of Medicine and Allied Health Sciences, University of The Gambia, Independence Drive, Banjul, Gambia.
² Ph.D. Program for Translational Medicine, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan.
³ Department of Public Health, Chang Gung University, Taoyuan, Taiwan; Department of Nutrition and Health Sciences, Chang Gung University of Science and Technology, Taoyuan, Taiwan; Research Center for Chinese Herbal Medicine, College of Human Ecology, Chang Gung University of Science and Technology, Taoyuan, Taiwan.
⁴ School of Public Health, College of Public Health, Taipei Medical University, Taipei, Taiwan.
⁵ Department of Otolaryngology, Chang Gung Memorial Hospital, Keelung, Taiwan.
⁶ Department of Public Health, Chang Gung University, Taoyuan, Taiwan; Department of Otolaryngology, Head and Neck Surgery, Chang Gung Memorial Hospital, Linkou, Taoyuan, Taiwan. Electronic address: shiangfu.huang@gmail.com.
⁷ School of Public Health, College of Public Health, Taipei Medical University, Taipei, Taiwan; Department of Public Health, College of Public Health, China Medical University, Taichung, Taiwan; Cancer Center, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan; Master Program in Applied Molecular Epidemiology, College of Public Health, Taipei Medical University, Taipei, Taiwan. Electronic address: ccyeh@tmu.edu.tw.

PMID: 33144272
DOI: 10.1016/j.gene.2020.145283

Abstract

Objective: To investigate the association between the variants of DNA double-strand break repair genes and the clinical outcomes of patients with oral squamous cell carcinoma (OSCC) undergoing concurrent chemoradiotherapy.

Methods: Five variants of DNA double-strand break repair genes in samples from 319 patients with OSCC were genotyped using the Sequenom iPLEX MassARRAY system. Kaplan-Meier curves and Cox proportional hazards analysis were used to identify the factors associated with patient survival.

Results: The XRCC2 rs2040639 (G3063A) polymorphism in the codominant model was associated with decreased recurrence risk (hazard ratio [HR] = 0.55, 95% confidence interval [CI] = 0.31-0.98; p = 0.042). A marginally significant interaction was observed between XRCC2 rs2040639 and PRKDC rs7003908 in patients carrying the AA and AA genotypes; these patients showed reduced recurrence risk (HR = 0.36, 95% CI = 0.17-0.79; p = 0.010).

Conclusion: The A-allele of XRCC2 rs2040639 is a favorable prognostic factor for disease-free survival. Patients with these genotypes may benefit from concurrent chemoradiotherapy. Additional confirmation from studies with larger samples or other ethnic populations is warranted.

Keywords: Chemotherapy; DNA double-strand break; Genetic polymorphisms; Radiotherapy.

MeSH terms

Chemoradiotherapy / methods*
DNA Breaks, Double-Stranded
DNA Repair / genetics*
DNA-Binding Proteins / genetics*
Disease-Free Survival
Female
Genetic Predisposition to Disease / genetics
Genotype
Humans
Male
Middle Aged
Mouth Neoplasms / genetics*
Mouth Neoplasms / therapy*
Polymorphism, Single Nucleotide / genetics
Squamous Cell Carcinoma of Head and Neck / genetics*
Squamous Cell Carcinoma of Head and Neck / therapy

Substances

DNA-Binding Proteins
XRCC2 protein, human